Two out of three individuals living with HIV/AIDS worldwide reside in sub-Saharan Africa (SSA). Fortunately, due to a massive roll-out of potent combination Antiretroviral Therapy (cART), global rates of morbidity and mortality from HIV infection have declined significantly over the past decade. However, while the initiation of cART has led to a global decline in deaths from AIDS related opportunistic infections and malignancies, there has correspondingly been a surge in deaths from cardiovascular disease (CVD) and non- AIDS related cancers. In North American cohorts up to 10% of all deaths among people with HIV/AIDS have been attributed to CVD. The greater frequency of CVD complications among HIV patients is thought to be possibly due to HIV-stimulated endothelial activation, vasculopathies, opportunistic infections, neoplasia, prothrombosis, and metabolic derangements or cART directly causing immune activation and metabolic dysfunction that can accelerate systemic atherosclerosis. There is a striking paucity of data on the nature and contributors to CVD among HIV patients in SSA. Beyond the potential contributions of the virus or cART to CVD risk in HIV patients, enhancements in the socio-economic status of general populations in SSA has led to an increasing adoption of Western diets and lifestyles resulting in a growing epidemic of key CVD risk factors such as hypertension, diabetes mellitus and dyslipidemia. Information on the prevalence and predictors of co-existing CVD among HIV patients in SSA could permit the development of unique strategies to reduce CVD burden in these patients encountered in resource-limited settings. Currently, HIV patients cared for in SSA are not routinely or systematically screened/treated for CVD because of socioeconomic obstacles, cultural barriers, under- diagnosis, and a dearth of scientific information to guide providers. The overall objective of the Evaluation of Vascular Event Risk while on Long-term Anti-retroviral Suppressive Therapy (EVERLAST) study is to characterize the presence of CVD risk among 240 HIV subjects on cART in SSA (vs. 240 cART-nave HIV patients and 240 HIV-uninfected subjects) and explore factors influencing it, while building sustainable capacity for a future intervention study across the lifespan in a resource-limited setting (Ghana). In EVERLAST, we will 1) assess the prevalence of CVD risk among HIV patients on cART for >1 year as defined by carotid intima media thickness, along with socio-econo-demographic factors, traditional CVD medical and lifestyle risk factors, HIV- related factors, and serologic indices; 2) we will obtain information and guidance about the barriers and facilitators influencing CVD risk management among HIV patients in SSA at the various levels of a social ecological model; and 3) based on data gathered from the earlier phases of the study, we will propose interventions at levels of the social ecological model to improve optimal CVD risk management of HIV patients on cART in SSA that can be tested in a future study.

Public Health Relevance

Combination therapies to suppress the activity of the HIV virus have considerably improved outcomes for HIV patients and turned the approach towards HIV treatment to one of chronic disease management. However, with longer survival rates, potentially direct effects of the virus, and possible side effects of HIV suppressive drugs, there has been a surge in the occurrence of cardiovascular disease among HIV patients. This research seeks to explore the presence of cardiovascular disease in a region where HIV/AIDS is most prevalent, i.e. sub-Saharan Africa, and develop culturally-acceptable and effective programs to reduce the burden of cardiovascular disease on the lives of these patients.

Agency
National Institute of Health (NIH)
Institute
Fogarty International Center (FIC)
Type
Exploratory/Developmental Grants (R21)
Project #
7R21TW010479-03
Application #
9884509
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Michels, Kathleen M
Project Start
2018-08-11
Project End
2019-12-31
Budget Start
2018-08-11
Budget End
2019-12-31
Support Year
3
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Northern California Institute Research & Education
Department
Type
DUNS #
613338789
City
San Francisco
State
CA
Country
United States
Zip Code
94121
Sarfo, Fred S; Ulasavets, Uladzislau; Opare-Sem, Ohene K et al. (2018) Tele-Rehabilitation after Stroke: An Updated Systematic Review of the Literature. J Stroke Cerebrovasc Dis 27:2306-2318
Sarfo, Fred S; Adusei, Nathaniel; Ampofo, Michael et al. (2018) Pilot trial of a tele-rehab intervention to improve outcomes after stroke in Ghana: A feasibility and user satisfaction study. J Neurol Sci 387:94-97
Sarfo, Fred S; Akassi, John; Kyem, Gloria et al. (2018) Long-Term Outcomes of Stroke in a Ghanaian Outpatient Clinic. J Stroke Cerebrovasc Dis 27:1090-1099
Sarfo, Fred S; Owusu, Dorcas; Adamu, Sheila et al. (2018) Plasma Glial Fibrillary Acidic Protein, Copeptin, and Matrix Metalloproteinase-9 Concentrations among West African Stroke Subjects Compared with Stroke-Free Controls. J Stroke Cerebrovasc Dis 27:633-644
Park, J-H; Ovbiagele, B (2017) Post-stroke diastolic blood pressure and risk of recurrent vascular events. Eur J Neurol 24:1416-1423
Sarfo, Fred Stephen; Jenkins, Carolyn; Singh, Arti et al. (2017) Post-stroke depression in Ghana: Characteristics and correlates. J Neurol Sci 379:261-265
Lekoubou, Alain; Ovbiagele, Bruce (2017) PREVALANCE AND INFLUENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE ON STROKE OUTCOMES IN HOSPITALIZED STROKE PATIENTS. eNeurologicalSci 6:21-24
Sarfo, Fred S; Adamu, Sheila; Awuah, Dominic et al. (2017) Potential role of tele-rehabilitation to address barriers to implementation of physical therapy among West African stroke survivors: A cross-sectional survey. J Neurol Sci 381:203-208
Sarfo, Fred Stephen; Jenkins, Carolyn; Mensah, Nathaniel Adusei et al. (2017) Prevalence and Predictors of Sleep Apnea Risk among Ghanaian Stroke Survivors. J Stroke Cerebrovasc Dis 26:1602-1608
Owolabi, Mayowa; Sarfo, Fred; Howard, Virginia J et al. (2017) Stroke in Indigenous Africans, African Americans, and European Americans: Interplay of Racial and Geographic Factors. Stroke 48:1169-1175

Showing the most recent 10 out of 14 publications